BridgeBio Pharma will host a webinar on limb-girdle muscular dystrophy with Dr. Matthew Wicklund on July 11, 2025.
Quiver AI Summary
BridgeBio Pharma, Inc. announced it will host an investor webinar on July 11, 2025, at 8:00 am ET, featuring Dr. Matthew Wicklund from the University of Texas Health Science Center. The webinar will focus on limb-girdle muscular dystrophy (LGMD), particularly LGMD type 2I/R9, highlighting the disease burden and unmet medical needs. Dr. Wicklund, an expert in the field with extensive clinical trial experience, will be joined by BridgeBio executives to discuss the progress of the company's treatment candidate BBP-418 and expectations for Phase 3 interim analysis results later in 2025. The webinar will be accessible via BridgeBio's website, along with a replay available for 30 days post-event.
Potential Positives
- Announcement of an investor webinar featuring a leading expert, Dr. Matthew Wicklund, which highlights the company's commitment to transparency and engagement with stakeholders.
- Discussion of the notable progress of BBP-418, a key drug candidate targeting LGMD2I/R9, indicating ongoing advancements in the company’s product development pipeline.
- Focus on limb-girdle muscular dystrophy, a rare genetic disease with significant unmet medical needs, showcasing BridgeBio's dedication to addressing serious health challenges.
- Opportunity for investors to gain insights into upcoming Phase 3 interim analysis results, which could influence future investment and research directions.
Potential Negatives
- None
FAQ
What is the date and time of the BridgeBio investor webinar?
The BridgeBio investor webinar is scheduled for July 11, 2025, at 8:00 am ET.
How can I access the live webinar for BridgeBio?
You can access the live webcast on the “Events & Presentations” page within the Investors section of the BridgeBio website.
Who will be presenting at the BridgeBio investor webinar?
Matthew Wicklund, M.D., will be presenting at the investor webinar, focusing on limb-girdle muscular dystrophy (LGMD).
What will be discussed regarding LGMD during the webinar?
The discussion will cover the disease burden, standard of care, and unmet needs for LGMD type 2I/R9.
Will there be a recording of the webinar available?
A replay of the webinar will be available on the BridgeBio website for 30 days following the event.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BBIO Insider Trading Activity
$BBIO insiders have traded $BBIO stock on the open market 25 times in the past 6 months. Of those trades, 0 have been purchases and 25 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:
- GENETIC DISORDER L.P. KKR has made 0 purchases and 2 sales selling 12,000,000 shares for an estimated $402,960,000.
- GLOBAL INVESTORS LP VIKING sold 3,065,616 shares for an estimated $106,989,998
- NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 12 sales selling 957,699 shares for an estimated $34,146,354.
- ANDREW LO sold 100,000 shares for an estimated $3,849,900
- BRIAN C STEPHENSON (CFO and Treasurer) has made 0 purchases and 4 sales selling 80,648 shares for an estimated $2,899,849.
- ANDREA ELLIS has made 0 purchases and 2 sales selling 40,000 shares for an estimated $1,371,500.
- HANNAH VALANTINE has made 0 purchases and 2 sales selling 17,167 shares for an estimated $591,179.
- MARICEL APULI (Chief Accounting Officer) sold 1,026 shares for an estimated $39,509
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BBIO Hedge Fund Activity
We have seen 189 institutional investors add shares of $BBIO stock to their portfolio, and 134 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KOHLBERG KRAVIS ROBERTS & CO. L.P. removed 6,000,000 shares (-23.8%) from their portfolio in Q1 2025, for an estimated $207,420,000
- VIKING GLOBAL INVESTORS LP removed 3,065,616 shares (-12.2%) from their portfolio in Q1 2025, for an estimated $105,978,345
- JANUS HENDERSON GROUP PLC added 2,263,866 shares (+46.1%) to their portfolio in Q1 2025, for an estimated $78,261,847
- DEEP TRACK CAPITAL, LP added 1,980,838 shares (+241.8%) to their portfolio in Q1 2025, for an estimated $68,477,569
- CITADEL ADVISORS LLC added 1,675,672 shares (+133.5%) to their portfolio in Q1 2025, for an estimated $57,927,981
- FARALLON CAPITAL MANAGEMENT LLC added 1,536,000 shares (+36.6%) to their portfolio in Q1 2025, for an estimated $53,099,520
- DRIEHAUS CAPITAL MANAGEMENT LLC added 1,500,558 shares (+inf%) to their portfolio in Q1 2025, for an estimated $51,874,290
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BBIO Analyst Ratings
Wall Street analysts have issued reports on $BBIO in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wolfe Research issued a "Outperform" rating on 06/17/2025
- UBS issued a "Buy" rating on 04/30/2025
To track analyst ratings and price targets for $BBIO, check out Quiver Quantitative's $BBIO forecast page.
Full Release
PALO ALTO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, July 11, 2025 at 8:00 am ET with Matthew Wicklund, M.D., FAAN, Professor of Neurology and Vice Chair for Research, Department of Neurology at the University of Texas (UT) Health Science Center San Antonio.
Dr. Wicklund will provide an overview of limb-girdle muscular dystrophy (LGMD), specifically focusing on the disease burden, standard of care and unmet needs for those with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) (FKRP-related). He serves as director for the UT Health San Antonio MDA Multidisciplinary Care Center and is a member of the Limb-girdle Muscular Dystrophy Clinical Research Network and the Neuromuscular Study Group. Dr. Wicklund has participated in over 35 multi-center clinical trials in the areas of muscular dystrophy, ALS, and myasthenia gravis and has over 200 published articles, chapters and abstracts.
In addition to Dr. Wicklund, executive members of the LGMD2I/R9 program will review the progress of BBP-418 to date and discuss expectations for the Phase 3 interim analysis results expected in the second half of 2025.
To access the live webcast of BridgeBio’s investor webinar, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com . A replay of the webcast will be available on the BridgeBio website for 30 days following the event.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit
bridgebio.com
and follow us on
LinkedIn
,
Twitter
,
Facebook
, and
YouTube
.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
[email protected]
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, VP Strategic Finance
[email protected]
